A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Enpatoran (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEPTUNIA
- Sponsors EMD Serono Research & Development Institute
Most Recent Events
- 18 Apr 2025 Planned End Date changed from 30 Apr 2025 to 30 Jun 2025.
- 18 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Jun 2025.
- 26 Nov 2024 Planned End Date changed from 4 Dec 2024 to 30 Apr 2025.